Rocket Pharmaceuticals, Inc. Investing Cash Flow
Rocket Pharmaceuticals, Inc. (RCKT) reported Investing Cash Flow of $231.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $214.36M, a 574.92% increase year-over-year.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $17.45M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $36.42M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $93.62M, a 18.62% increase year-over-year.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $103.77M, a 21.21% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $131.71M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$98.07M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$69.33M, a 467.72% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $214.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $231.81M 10-Q · filed 2026-08-10 | $268.23M derived: sum of 3 quarters · filed 2026-08-10 | $361.85M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $17.45M 10-Q · filed 2026-05-07 | $53.87M derived: sum of 2 quarters · filed 2026-05-07 | $147.49M derived: sum of 3 quarters · filed 2026-05-07 | $179.25M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $36.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $130.04M derived: sum of 2 quarters · filed 2026-02-26 | $161.80M derived: sum of 3 quarters · filed 2026-08-10 | $103.77M 10-K · filed 2026-02-26 |
| 2025-09-30 | $93.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $125.38M derived: sum of 2 quarters · filed 2026-08-10 | $67.34M 10-Q · filed 2025-11-06 | $29.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $31.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$26.27M 10-Q · filed 2026-08-10 | -$64.14M derived: sum of 3 quarters · filed 2026-08-10 | $14.77M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$58.03M 10-Q · filed 2026-05-07 | -$95.91M derived: sum of 2 quarters · filed 2026-05-07 | -$16.99M derived: sum of 3 quarters · filed 2026-05-07 | $38.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$37.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $41.05M derived: sum of 2 quarters · filed 2026-02-26 | $96.67M derived: sum of 3 quarters · filed 2026-02-26 | $131.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $78.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $134.54M derived: sum of 2 quarters · filed 2025-11-06 | $169.58M 10-Q · filed 2025-11-06 | $28.77M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $55.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $90.66M 10-Q · filed 2025-08-07 | -$50.15M derived: sum of 3 quarters · filed 2025-08-07 | -$1.89M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $35.03M 10-Q · filed 2025-05-08 | -$105.77M derived: sum of 2 quarters · filed 2025-05-08 | -$57.52M derived: sum of 3 quarters · filed 2025-05-08 | -$26.31M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$140.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$92.55M derived: sum of 2 quarters · filed 2025-02-27 | -$61.34M derived: sum of 3 quarters · filed 2025-02-27 | -$98.07M 10-K · filed 2025-02-27 |
| 2023-09-30 | $48.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $79.46M derived: sum of 2 quarters · filed 2024-11-07 | $42.74M 10-Q · filed 2024-11-07 | -$65.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $31.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$5.51M 10-Q · filed 2024-08-06 | -$114.10M derived: sum of 3 quarters · filed 2025-02-27 | -$90.64M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$36.72M 10-Q · filed 2024-05-07 | -$145.31M derived: sum of 2 quarters · filed 2025-02-27 | -$121.84M derived: sum of 3 quarters · filed 2025-02-27 | -$43.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$108.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$85.12M derived: sum of 2 quarters · filed 2025-02-27 | -$6.33M derived: sum of 3 quarters · filed 2025-02-27 | -$69.33M 10-K · filed 2025-02-27 |
| 2022-09-30 | $23.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $102.25M derived: sum of 2 quarters · filed 2023-11-07 | $39.26M 10-Q · filed 2023-11-07 | $56.12M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $78.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $15.79M 10-Q · filed 2023-08-09 | $32.66M derived: sum of 3 quarters · filed 2024-02-27 | $14.47M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$62.99M 10-Q · filed 2023-05-05 | -$46.13M derived: sum of 2 quarters · filed 2024-02-27 | -$64.32M derived: sum of 3 quarters · filed 2024-02-27 | -$14.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $16.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.32M derived: sum of 2 quarters · filed 2024-02-27 | $48.03M derived: sum of 3 quarters · filed 2024-02-27 | $18.85M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$18.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $31.16M derived: sum of 2 quarters · filed 2022-11-04 | $1.99M 10-Q · filed 2022-11-04 | -$52.47M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $49.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $20.18M 10-Q · filed 2022-08-09 | -$34.28M derived: sum of 3 quarters · filed 2023-02-28 | -$98.48M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$29.17M 10-Q · filed 2022-05-06 | -$83.64M derived: sum of 2 quarters · filed 2023-02-28 | -$147.83M derived: sum of 3 quarters · filed 2023-02-28 | -$153.26M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$54.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$118.66M derived: sum of 2 quarters · filed 2023-02-28 | -$124.09M derived: sum of 3 quarters · filed 2023-02-28 | -$96.59M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$64.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$69.63M derived: sum of 2 quarters · filed 2021-11-05 | -$42.13M 10-Q · filed 2021-11-05 | -$18.61M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$5.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $22.06M 10-Q · filed 2021-08-09 | $45.58M derived: sum of 3 quarters · filed 2022-02-28 | $80.76M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $27.50M 10-Q · filed 2021-05-10 | $51.01M derived: sum of 2 quarters · filed 2022-02-28 | $86.19M derived: sum of 3 quarters · filed 2022-02-28 | -$40.69M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $23.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $58.69M derived: sum of 2 quarters · filed 2022-02-28 | -$68.19M derived: sum of 3 quarters · filed 2022-02-28 | -$39.01M 10-K · filed 2022-02-28 |
| 2019-09-30 | $35.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$91.70M derived: sum of 2 quarters · filed 2020-11-06 | -$62.52M 10-Q · filed 2020-11-06 | -$43.48M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$126.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$97.70M 10-Q · filed 2020-08-05 | -$78.66M derived: sum of 3 quarters · filed 2021-03-01 | -$81.64M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $29.18M 10-Q · filed 2020-05-08 | $48.22M derived: sum of 2 quarters · filed 2021-03-01 | $45.24M derived: sum of 3 quarters · filed 2021-03-01 | -$62.17M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $19.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $16.06M derived: sum of 2 quarters · filed 2021-03-01 | -$91.35M derived: sum of 3 quarters · filed 2021-03-01 | -$5.27M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$2.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$110.40M derived: sum of 2 quarters · filed 2019-11-08 | -$24.32M 10-Q · filed 2019-11-08 | -$24.35M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | -$107.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$21.34M 10-Q · filed 2019-08-08 | -$21.37M derived: sum of 3 quarters · filed 2019-08-08 | -$21.37M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $86.08M 10-Q · filed 2019-05-09 | $86.05M derived: sum of 2 quarters · filed 2019-05-09 | $86.05M derived: sum of 3 quarters · filed 2019-05-09 | $85.45M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$31.00K derived: sum of 2 quarters · filed 2019-03-08 | -$629.00K derived: sum of 3 quarters · filed 2019-03-08 | -$760.00K 10-K · filed 2019-03-08 |
| 2017-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$599.00K derived: sum of 2 quarters · filed 2018-11-09 | -$730.00K 10-Q · filed 2018-11-09 | |
| 2017-06-30 | -$598.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$729.00K 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | -$131.00K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | -$335.00K 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |